What Is Ectris (Flibanserin)?

What Is Ectris (Flibanserin, Girosa)?

Ectris (Flibanserin, Girosa) could be the first oral product for the treatment of HSDD (hypoactive sexual desire disorder in menopausal women) in the U.S.
Ectris (Flibanserin) works in the central nervous system, which regulates sexual desire.
Ectris (Flibanserin) acts as a 5-HT1A serotonin receptor agonist and 5-HT2A serotonin receptor antagonist.


Clinical studies are underway to better understand this investigational compound and how it may impact women with Hypoactive Sexual Desire Disorder (HSDD).


Ectris (flibanserin) Phase III Study Results

Ectris (Flibanserin) Phase III trials study presented at the Congress of the European Society for Sexual Medicine in Lyon, shows positive results with pre-menopausal women taking Ectris (flibanserin 100mg) once-daily at bedtime, increasing the number of Satisfying Sexual Events (SSEs) and decreasing significantly the distress associated with Hypoactive Sexual Desire Disorder (HSDD).
Phase III Clinical Trial Results in North America
Analysis of 1,378 pre-menopausal women taking Ectris (Flibanserin 100mg) during 24-week study period, shows significant increase in the frequency of Satisfying Sexual Events (SSEs) per month from 2.8 at baseline to 4.5 versus placebo 2.7 at baseline increasing to 3.7.
Other key secondary endpoints showed Ectris (flibanserin) significantly improved sexual functioning as measured by data from the desire domain of the Female Sexual Function Index (FSFI).
Recently Boehringer Ingelheim presented new data from Phase III clinical trials of Ectris (Flibanserin 100 mg) at the 58th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists in San Francisco.
Ectris
(Flibanserin 100 mg)
New Phase III Data in USA reported positive results
Safety Analysis
Ectris (flibanserin 100mg) adverse events were mild to moderate, emerged during the first 14 days of treatment and resolved with continued treatment.
The most common adverse drug reactions reported by more women on Ectris (flibanserin) than on placebo included dizziness, nausea, fatigue, somnolence and insomnia.
Boehringer Ingelheim was conducting Phase III clinical trials evaluating Ectris (Flibanserin) in over 2,000 women at 360 locations in the USA, Canada and Europe.

Flibanserin’s effects are believed to improve a woman’s decreased sexual desire gradually over time and a Phase III study results programme show that Ectris (flibanserin 100mg) is well-tolerated and effective in pre-menopausal women suffering Hypoactive Sexual Desire Disorder (HSDD).


USA Flibanserin 100 mg active clinical trials

Women 18 to 55 years of age diagnosed with Hypoactive Sexual Desire Disorder with a monogamous heterosexual relationship for at least one year, can now participate in clinical trials across the USA and Canada to test the safety and efficacy of flibanserin 100 mg in naturally postmenopausal women.
For further information visit the following link:

http://clinicaltrials.gov/ct2/results?term=flibanserin&recr=Open&s



Ectris (Flibanserin, Girosa ) Side Effects
Phase III Clinical Trials ResultsGirosa (flibanserin 100mg) adverse events were mild to moderate, emerged during the first 14 days of treatment and resolved with continued treatment.
The most common side effects reported by more women on Ectris (flibanserin) than on placebo included dizziness, nausea, fatigue, somnolence and insomnia.

Can I buy Ectris Girosa (flibanserin, Girosa )?
No, Ectris (Flibanserin) is not yet available for sale.